Local false discovery rate facilitates comparison of different microarray experiments

por Hong, Wan-Jen, Tibshirani, Robert, Chu, Gilbert
Publicado 2009

Centrosome-Kinase Fusions Promote Oncogenic Signaling and Disrupt Centrosome Function in Myeloproliferative Neoplasms

por Lee, Joanna Y., Hong, Wan-Jen, Majeti, Ravindra, Stearns, Tim
Publicado 2014

Front‐line treatment patterns in multiple myeloma: An analysis of U.S.‐based electronic health records from 2011 to 2019

por Kumar, Shaji, Williamson, Mellissa, Ogbu, Uzor, Surinach, Andy, Arndorfer, Stella, Hong, Wan‐Jen
Publicado 2021

A Humanized Ossicle-niche Xenotransplantation Model Enables Improved Human Leukemic Engraftment

por Reinisch, Andreas, Thomas, Daniel, Corces, M. Ryan, Zhang, Xiaohua, Gratzinger, Dita, Hong, Wan-Jen, Schallmoser, Katharina, Strunk, Dirk, Majeti, Ravindra
Publicado 2016

Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis

por Atrash, Shebli, Flahavan, Evelyn M., Xu, Tao, Ma, Esprit, Karve, Sudeep, Hong, Wan-Jen, Jirau-Lucca, Gilbert, Nixon, Michael, Ailawadhi, Sikander
Publicado 2022

RWD-derived response in multiple myeloma

por Xu, Tao, Roose, James, Williamson, Mellissa, Sawas, Ahmed, Hong, Wan-Jen, Jin, Huan, Maignan, Kathleen, Rocci, Alberto, Yousefi, Kasra, Kumar, Shaji, Tyanova, Stefka
Publicado 2023

NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity

por Richards, Rebecca M., Zhao, Feifei, Freitas, Katherine A., Parker, Kevin R., Xu, Peng, Fan, Amy, Sotillo, Elena, Daugaard, Mads, Oo, Htoo Zarni, Liu, Jie, Hong, Wan-Jen, Sorensen, Poul H., Chang, Howard Y., Satpathy, Ansuman T., Majzner, Robbie G., Majeti, Ravindra, Mackall, Crystal L.
Publicado 2021

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

por Wei, Andrew H., Strickland, Stephen A., Hou, Jing-Zhou, Fiedler, Walter, Lin, Tara L., Walter, Roland B., Enjeti, Anoop, Tiong, Ing Soo, Savona, Michael, Lee, Sangmin, Chyla, Brenda, Popovic, Relja, Salem, Ahmed Hamed, Agarwal, Suresh, Xu, Tu, Fakouhi, Kaffa M., Humerickhouse, Rod, Hong, Wan-Jen, Hayslip, John, Roboz, Gail J.
Publicado 2019

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma

por Kaufman, Jonathan L., Gasparetto, Cristina, Schjesvold, Fredrik H., Moreau, Philippe, Touzeau, Cyrille, Facon, Thierry, Boise, Lawrence H., Jiang, Yanwen, Yang, Xiaoqing, Dunbar, Fengjiao, Vishwamitra, Deeksha, Unger, Stefanie, Macartney, Tammy, Pesko, John, Yu, Yao, Salem, Ahmed Hamed, Ross, Jeremy A., Hong, Wan‐Jen, Maciag, Paulo C., Pauff, James M., Kumar, Shaji
Publicado 2021

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

por Daver, Naval G., Dail, Monique, Garcia, Jacqueline S., Jonas, Brian A., Yee, Karen W. L., Kelly, Kevin R., Vey, Norbert, Assouline, Sarit, Roboz, Gail J., Paolini, Stefania, Pollyea, Daniel A., Tafuri, Agostino, Brandwein, Joseph M., Pigneux, Arnaud, Powell, Bayard L., Fenaux, Pierre, Olin, Rebecca L., Visani, Giuseppe, Martinelli, Giovanni, Onishi, Maika, Wang, Jue, Huang, Weize, Green, Cherie, Ott, Marion G., Hong, Wan-Jen, Konopleva, Marina Y., Andreeff, Michael
Publicado 2023